Mark Rubinstein, MD

Mark L. Rubinstein, MD is the Chief Medical Officer at AchieveRx, bringing more than two decades of experience in clinical medicine, scientific research and medical affairs leadership, with a strong focus on nicotine cessation and preventive medicine. Prior to joining AchieveRx, Mark served as the Head of Medical Affairs at Blip, where he spearheaded the company’s strategy to help smokers and vapers quit through FDA-approved medications and digital support tools. He was also Vice President of Global Scientific Affairs at Juul Labs, where he led efforts to prevent youth usage of nicotine products. Mark is Professor Emeritus of Pediatrics at the University of California, San Francisco (UCSF), where his NIH-funded research advanced understanding of adolescent nicotine addiction and smoking cessation interventions. He earned his MD from Yale School of Medicine, completed his Internal Medicine residency at Yale–New Haven Hospital, and is board certified in Internal Medicine and Adolescent Medicine.